Answers are grounded in this paper and cite their sources.
// João Agostinho Machado-Neto 1 , Paula de Melo Campos 1 , Patricia Favaro 1, 2 , Mariana Lazarini 1, 2 , Adriana da Silva Santos Duarte 1 , Irene Lorand-Metze 1 , Fernando Ferreira Costa 1 , Sara Teresinha Olalla Saad 1 , Fabiola Traina 1, 3 1 Hematology and Hemotherapy Center, University of Campinas/Hemocentro-Unicamp, Instituto Nacional de Ciência e Tecnologia do Sangue, Campinas, São Paulo, Brazil 2 Current address: Department of Biological Sciences, Federal University of São Paulo, Diadema, São Paulo, Brazil 3 Current address: Department of Internal Medicine, University of São Paulo at Ribeirão Preto Medical School, Ribeirão Preto, São Paulo, Brazil Correspondence to: Fabiola Traina, e-mail: ftraina@fmrp.usp.br ; e-mail: fabiolatraina@gmail.com Keywords: myeloproliferative neoplasms, STAT3, stathmin 1, ruxolitinib, paclitaxel Received: February 27, 2015 Accepted: August 11, 2015 Published: August 24, 2015 ABSTRACT The JAK/STAT pathway is constitutively activated in myeloproliferative neoplasms and can be inhibited by ruxolitinib, a selective JAK1/2 inhibitor. The JAK2 V617F mutation leads to constitutive STAT3 phosphorylation and potentially leads to inhibition of Stathmin 1 activity via STAT3. In support of this hypothesis, we found that, in HEL JAK2 V617F cells, ruxolitinib treatment decreased STAT3 and Stathmin 1 association, induced Stathmin 1 activation and microtubule instability. Silencing of Stathmin 1 significantly reduced cell proliferation and clonal growth, and increased apoptosis induced by ruxolitinib. Stathmin 1 silencing also prevented ruxolitinib-induced microtubule instability. To phenocopy the effect of Stathmin 1 inhibition, cells were treated with paclitaxel, a microtubule-stabilizing drug, in association or not with ruxolitinib; combined treatment significantly increased apoptosis, when compared to monotherapy. Notably, Stathmin 1 mRNA levels were highly expressed in CD34 + cells from primary myelofibrosis patients. We then proposed that an undesired effect of ruxolitinib treatment may constitute Stathmin 1 activation and microtubule instability in JAK2 V617F cells. Induction of microtubule stability, through Stathmin 1 silencing or paclitaxel treatment, combined with ruxolitinib could be an effective strategy for promoting apoptosis in JAK2 V617F cells.
No takes yet. Share an insight, caveat, or question.
Machado‐Neto et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: